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ABSTRACT
ObjectiveaaNeurodegeneration with brain iron accumulation (NBIA) represents a group of inherited movement disorders char-
acterized by iron accumulation in the basal ganglia. Recent advances have included the identification of new causative genes and 
highlighted the wide phenotypic variation between and within the specific NBIA subtypes. This study aimed to investigate the 
current status of NBIA in Korea.
MethodsaaWe collected genetically confirmed NBIA patients from twelve nationwide referral hospitals and from a review of the 
literature. We conducted a study to describe the phenotypic and genotypic characteristics of Korean adults with atypical pantothe-
nate kinase-associated neurodegeneration (PKAN). 
ResultsaaFour subtypes of NBIA including PKAN (n = 30), PLA2G6-related neurodegeneration (n = 2), beta-propeller protein-
associated neurodegeneration (n = 1), and aceruloplasminemia (n = 1) have been identified in the Korean population. The clinical 
features of fifteen adults with atypical PKAN included early focal limb dystonia, parkinsonism-predominant feature, oromandib-
ular dystonia, and isolated freezing of gait (FOG). Patients with a higher age of onset tended to present with parkinsonism and 
FOG. The p.R440P and p.D378G mutations are two major mutations that represent approximately 50% of the mutated alleles. Al-
though there were no specific genotype-phenotype correlations, most patients carrying the p.D378G mutation had a late-onset, 
atypical form of PKAN.
ConclusionsaaWe found considerable phenotypic heterogeneity in Korean adults with atypical PKAN. The age of onset may in-
fluence the presentation of extrapyramidal symptoms.
Key WordsaaIron; Neurodegenerative diseases; Pantothenate kinase-associated neurodegeneration; Phenotype; Allele frequency.
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Neurodegeneration with brain iron accumulation 
(NBIA) represents a group of inherited disorders ch-
aracterized by iron deposition in the brain, and 
NBIA exhibits the clinical features of movement dis-
orders.1 Over the last decade, several causative genes, 
directly involved in iron homeostasis, mitochondrial 
function, lipid metabolism, and autophagic activity, 
have been identified including FTL, CP, PANK2, 
PLA2G6, C19orf12, COASY, FA2H, WDR45, and 
ATP13A2.2 Of the known causes of NBIA, the most 
common cause of NBIA is pantothenate kinase-as-
sociated neurodegeneration (PKAN) due to muta-
tions in the PANK2 gene, followed by PLA2G6-re-
lated neurodegeneration (PLAN) due to mutations 
in the PLA2G6 gene.1,3 The diagnosis of NBIA is 
made by combining clinical features and magnetic 
resonance imaging evidence of iron accumulation in 
the brain.3
NBIA patients commonly exhibit mixed extrapy-
ramidal and pyramidal features.1,4 However, the clin-
ical spectrum ranges from global neurodevelopmen-
tal delay in infancy to dystonia-parkinsonism in ad-
ulthood, with wide phenotypic variability within 
the specific NBIA subtypes.1,3,5 In PKAN, the classic 
form is characterized by early childhood onset with 
rapid progression.1,6 The atypical variant presents in 
the second or third decade of life with less severe 
and slow-progressive extrapyramidal and pyrami-
dal signs.1,6 Cognitive impairment and neuropsy-
chiatric symptoms may be prominent.1,6 Similar age-
dependent presentations have also been recognized 
in PLAN.1,3,4 Adult-onset NBIA may also mimic the 
clinical presentations of other neurodegenerative dis-
eases, making the diagnosis challenging.4 
To date, reports on the clinical and genetic profile 
of Korean patients with NBIA have been restricted 
to single cases or case series that were lacking in de-
tailed data.7-18 To investigate the current status of 
NBIA in Korea, we collected NBIA data from twelve 
nationwide referral hospitals and from a review of 
the literature. We also conducted a study to describe 
the phenotypic and genotypic characteristics of Ko-
rean adults with atypical PKAN. 
 
 MATERIALS & METHODS
This study was approved by the Ethical Commit-
tee of the Pusan National University Yangsan Hospi-
tal. We recruited thirty-four Korean patients with ge-
netically determined NBIA using a structural survey 
and a literature review of published case reports. A 
nationwide survey was organized by the Korean 
Movement Disorders Society. For PKAN, nine new 
cases and twenty-one previously published cases 
from twenty-eight families were collected. Among 
these cases, sixteen patients were classified as hav-
ing an atypical disease according to the criteria of 
Hayflick et al.6 Three pediatric patients who had 
typical clinical features of PKAN and the eye-of-the-
tiger sign carried only one heterozygous missense 
mutation that was detected by direct sequencing of 
the PANK2 gene. Two siblings with PLAN and one 
patient with beta-propeller protein-associated neu-
rodegeneration (BPAN) were recently described in 
the literature.16,18 One unpublished case of acerulo-
plasminemia, a 60-year-old female presenting with 
dystonia, chorea, and dementia, was included in the 
present study. 
We collected detailed clinical data on fifteen adult 
PKAN patients from fourteen unrelated families. 
Genomic DNA from all patients was sequenced for 
PANK2 mutations. For the numbering of the muta-
tions, all published and unpublished cases were ad-
justed by comparison with the wild-type nucleotide 
and amino acid sequences (GenBank ID: NM_ 
153638.2, NP_705902.2). For analysis of the clinical 
and genetic data, the medical records of five new 
patients from 4 referral hospitals were reviewed. We 
also attempted to contact the authors of the publi-
cations to update the clinical information, and we 
obtained additional follow-up data from six pub-
lished cases.8,12-15 We analyzed the following clinical 
information: age at onset of the disease, age at diag-
nosis, age at the last evaluation, presenting symp-
toms, and clinical characteristics at the last evalua-
tion including dystonia, tremor, parkinsonism, gait/
posture, pyramidal signs, bulbar symptoms, cogni-
tive/behavioral changes, results of ophthalmologic 
examinations, peripheral blood smears, neuroim-
aging findings, mutations in the PANK2 gene, re-
sponse to treatment, and disease course. Fourteen 
pediatric patients with typical PKAN were exclud-
ed from this clinical data analysis because of insuf-
ficient clinical or genetic information. Instead, we 
gathered genetic data from ten unrelated pediatric 
PKAN patients carrying two mutated alleles to in-
vestigate the differences in the mutation frequencies 
between the classic and atypical forms. 
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RESULTS
The clinical, neuroimaging and molecular results 
from fifteen patients (thirteen males and two females 
with the atypical form of PKAN) are summarized 
in Table 1 and Supplementary Table 1 (in the online-
only Data Supplement). The mean age at onset was 
31.1 ± 11.8 years (range 15–52 years), and the mean 
disease duration was 13.8 ± 9.7 years (range 1–34 
years). Patients 7 (P7) and 8 (P8) were siblings. Five 
patients declared that they had at least 1 family mem-
ber who was affected with similar symptoms. The 
remaining patients were presumed to be sporadic 
cases. The presenting symptoms were as follows: dif-
ficulty in writing or handling objects in ten patients 
(hand dystonia in six patients and hand tremor in 
four patients), gait disturbance in four patients [dys-
tonic gait in two patients, dystonic gait with freezing 
in one patient, and isolated freezing of gait (FOG) in 
one patient], speech changes in three patients (mo-
notonous speech, dysphonia, and dysarthria), and 
oromandibular dystonia (OMD) in one patient (jaw-
opening). Two patients presented with a rapid onset, 
OMD and painful dystonia (P2 and P7). 
At the last evaluation, the predominant neurolog-
ical features were dystonia and parkinsonism (eight 
patients with dystonia without parkinsonism, four 
patients with parkinsonism and dystonia, and two 
patients with parkinsonism without dystonia). Dys-
tonia most commonly involved the limbs (n = 12), 
often affecting the craniocervical musculature in-
cluding blepharospasm, cervical dystonia, and OMD 
(n = 8). Early focal limb dystonia progressed to in-
volve other limbs. Axial involvement, with retrocollis 
or truncal tilting, was not prominent in most of the 
patients. Gait and balance problems were very com-
mon (n = 12), unsteadiness and freezing were re-
ported in six and three patients, respectively. Al-
though some patients needed to use canes for 
walking, none of them completely lost the ability to 
walk. Speech disturbances, including dysarthria, pa-
lilalia and hypophonia, were frequent (n = 10) and 
presented from the early stage in three patients. Dys-
arthria was accompanied by dysphagia or drooling 
in four patients. Tremors (n = 9) were usually pos-
tural in nature and presented as dystonic tremors. 
Rest tremors were observed in two patients; one of 
them presented with parkinsonism (P13), and the 
other had unilateral leg tremors (P12). Corticospi-
nal tract signs (spasticity, hyperreflexia and exten-
sor plantar reflexes) were rarely described.
Other features including pigmentary retinopathy, 
acanthocytosis,19 and seizure were not mentioned in 
the medical records. Psychiatric symptoms with cog-
nitive decline were not prominent in most patients. 
Cognitive impairment was evident in two young 
siblings (P7 and P8). The results of neuropsycholog-
ical tests revealed mild mental retardation. The older 
brother showed psychiatric signs of obsessive-com-
pulsive disorder and attention-deficit and hyperac-
tivity disorder. Two patients who underwent neuro-
psychological testing had mild frontal dysfunction 
(P10 and P15). Three patients over 50 years of age 
presented with subjective memory complaints; how-
ever, neuropsychological tests were not performed. 
All had the eye-of-the-tiger sign on T2-weighted 
images. Marked hyperintensities on T1-weighted 
images in bilateral anteromedial globus pallidi were 
reported in two patients (P5 and P10). Susceptibili-
ty-weighted imaging dramatically revealed the evi-
dence of iron deposition restricted to the globus 
pallidus and substantia nigra (Figure 1). Dopamine 
transporter imaging with N-{3-[(18)F]fluoropropyl}-
2-carbomethoxy-3-(4-iodophenyl) nortropane posi-
Table 1. Clinical characteristics of Korean adults with atypical PKAN 
Gender (M:F) 13:2
Mean age of onset (years) 31.1 ± 11.8 (range 15–52)
Mean age at diagnosis (years) 40.6 ± 13.1 (range 15–55)
Mean disease duration (years) 13.8 ± 9.7 (range 1–34)
Initial symptoms (%)
Limb dystonia 60
Tremor 27
Speech change 20
OMD 7
FOG 13
Clinical findings at last evaluation (%)
Dystonia 80
Limbs 80
Craniocervical 53
Parkinsonism 40
With dystonia 27
Without dystonia 13
Tremor 60
Gait disturbance 80
Pyramidal signs 20
Dysarthria 67
Dysphagia 27
Cognitive impairment 27
Psychiatric symptoms 7
 OMD: oromandibular dystonia, FOG: freezing of gait, PKAN: pantothenate kinase-associ-
ated neurodegeneration. 
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tron emission tomography studies in two patients 
with parkinsonism (P13) and gait freezing (P15) re-
vealed no striatal dopamine depletion. No perfu-
sion defect was observed in one patient (P3).
There were no overt responses to conventional 
drugs used for the control of dystonia, tremor, or 
parkinsonism, although partial improvements were 
reported. In two patients with FOG as the main clin-
ical feature, FOG showed dramatic responses to me-
dications.7,17 One patient (P9) dramatically improv-
ed with trihexyphenidyl, and the other patient (P15) 
dramatically improved with methylphenidate. 
Three patients (P4, P7, and P10) underwent bilateral 
globus pallidus pars interna (GPi) deep brain stim-
ulation (DBS). All patients showed some improve-
ments in the clinical rating scales of dystonia and 
disability (Supplementary Table 1 in the online-only 
Data Supplement). The patient with rapid exacerba-
tion of painful dystonic spasms immediately un-
derwent bilateral GPi-DBS (P7). His axial and limb 
dystonia showed sustained improvement for up to 
5 years after DBS. However, he developed intracta-
ble jaw-opening OMD which severely interfered 
with speech and mastication. In two other patients 
(P4 and P10), disabling hand dystonia responded to 
DBS. Their functional improvement continued for 
3-year follow-up period. However, in one patient 
(P4, previously published), the effect disappeared 
four year after DBS. 
We identified 18 different mutations in 24 Kore-
an families with PKAN. Mutations were found in 
both PANK2 alleles and included missense muta-
tions (37/48 alleles), frameshift mutations (8/48 al-
leles), nonsense mutations (1/48 alleles), and dele-
tions (4/48 alleles) (Table 2). Most of the patients 
had compound heterozygous mutations. In two aty-
pical cases, one was homozygous (P12), and the oth-
er had two different missense mutations and one 
frameshift mutation (P13). An intragenic deletion 
ranging from exons 2 to 4 (c.629-?_1412+ ?del) was 
Figure 1. Brain MRI of patient 8. T2 hypointensity is not prominent in the sub-
stantia nigra (A). The T2-weighted image shows the typical eye-of-the-tiger sign 
with hypointensity with a central region of hyperintensity in the globus pallidus 
(B). Susceptibility-weighted images dramatically show iron-related hypointense 
signals from the substantia nigra to the globus pallidus (C and D). 
A  
C  
B  
D  
Table 2. Mutations in PANK2 gene
Atypical (n = 15*) Classic (n = 10)
Exon Genomic DNA Protein No. Exon Genomic DNA Protein No.
3 c.1133A > G p.D378G 10 4 c.1319G > C p.R440P 9
4 c.1319G > C p.R440P 8 5 c.1502T > A p.I501N 3
3 c.1003A > G p.K335E 3 3 c.1153delCinsTT p.L385fs 1
4 c.1273_1275del p.L425del 2 4 c.1273_1275del p.L425del 1
3 c.1153delCinsTT p.L385fs 2 4 c.1257del† p.F419fs 1
3 c.1154_1155insTT p.L385fs 1 1 c.391_418del p.A131fs 1
4 c.1270_1272del p.L424del 1 7  c.1676C > G† p.A559G 1
2 c.823_824del p.L275fs 1 4 c.1301C > T p.A434V 1
5 c.1500_1501del p.I501fs 1 2 c.852T > G p.F284L 1
4 c.1351C > T p.R451X 1 2 to 4 c.629-?_1412+ ?del‡ 1
6 c.1607A > G p.Y536C 1
Mutations were adjusted by comparison with the wild-type sequences (GenBank ID: NM_153638.2, NP_705902.2). *number of unrelated atypical patients in-
cluding one adolescence patient, †novel variants, possibly pathogenic, ‡an intragenic deletion. No.: number of alleles found in patients.
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found in a pediatric patient.15 The most frequent 
mutations identified were p.D378G (10/28 alleles) 
and p.R440P (8/28 alleles) in Korean adults with 
atypical PKAN (Table 2: atypical). Within the atypi-
cal group, there were no specific genotype-pheno-
type correlations. Five patients who were all compo-
und heterozygotes for these two mutations (p.
D378G and p.R440P) showed variable clinical man-
ifestations, including dystonia without parkinson-
ism (n = 2), dystonia with parkinsonism (n = 1), par-
kinsonism-predominant (n = 1), and isolated FOG 
(n = 1). Two siblings (P7 and P8) presented with dif-
ferent spreading patterns of dystonia, although they 
had a similar age at onset in the second decade. The 
older brother, initially, developed twisting postures 
in his right hand, whereas his younger brother had 
dystonia starting in the legs. 
In pediatric patients with typical PKAN, the most 
prevalent mutation was the p.R440P mutation (9/20 
alleles), followed by the p.I501N mutation (3/20 al-
leles) (Table 2: classic). Eight published cases ini-
tially presented with gait disturbance and general-
ized dystonia before 10 years of age. Half of them 
had lost ambulation within 3 years of onset.15 Three 
newly enrolled patients had dystonic opisthotonus 
and tip-toe gait. Two possibly pathogenic novel vari-
ants were identified (c.1676C > G, p.A559G and 
c.1257del, p.F419fs). One adolescence patient with 
atypical presentation had two compound heterozy-
gous mutations (c.1351C > T, p.R451X and c.1607A > 
G, p.Y536C).15 The allele frequencies of protein-trun-
cating mutations were not different between the 
two groups (Table 2). 
DISCUSSION
Among the ten forms of NBIA, four subtypes of 
NBIA including PKAN, PLAN, BPAN, and aceru-
loplasminemia have been identified in the Korean 
population. PKAN was the most common cause of 
NBIA. The characteristic eye-of-the-tiger sign of 
PKAN may aid in diagnosing this disorder.1,6 The 
other forms of NBIA were rare and were reported 
only in single cases.16,18 However, it may still be too 
early to determine the frequency and distribution 
of these disorders in the Korean population. Increas-
ing clinician awareness will improve early recogni-
tion and diagnosis of various types of NBIA.
All fifteen patients analyzed in this study could be 
classified as having atypical PKAN on the basis of 
late onset and slow progression.1,6 Patients with long-
lasting movement disorders exhibited similar func-
tional disabilities regardless of the disease duration 
and no significant functional declines during the 
past several years. None of them completely lose their 
ability to ambulate even after a disease duration of 
20 years or more. This observation is most likely re-
lated to the specific pattern of disease progression of 
atypical PKAN. The rate of decline tends to be steep-
er after the onset of symptoms, followed by a rela-
tively stable period of slower progression.1,20 
In addition to the age at onset and disease dura-
tion, other atypical features in our patients included 
early focal limb dystonia, tremor, parkinsonism, ch-
anges in speech patterns, OMD, and FOG. Early 
dystonia frequently involved a unilateral hand with 
manifestation of writer’s cramp or action-induced 
dystonia. Most of them slowly progressed to involve 
other limbs and, less commonly, craniocervical re-
gions. This initial distribution of dystonia is differ-
ent from that of patients with the classic form that 
predominantly affects the lower limbs. Dystonic 
opisthotonus, a hallmark of early-onset typical PK-
AN,21 was rare in our series. The presentation and 
progression of dystonia tends to differ between eth-
nic groups. As demonstrated by a previous report, 
OMD was less common than in Caucasians.20,22 In a 
recent prospective study, half of the patients devel-
oped dystonic opisthotonus within five years after 
onset.20 This disease course was more progressive 
than that observed in our patients. 
The parkinsonism-predominant phenotype was 
also the characteristic subgroup of our patients. They 
initially presented with hand tremor, even with a 
resting component, and were clinically indistin-
guishable from patients with degenerative parkin-
sonism. The results of normal striatal binding with 
dopamine transporter imaging are consistent with 
previous reports.23 Moreover, a neuropathological 
study identified only minimal loss of neuromelanin 
in the substantia nigra, while the central pallidum 
and substantia nigra pars reticulata were mainly in-
volved.24 Two major extrapyramidal symptoms of 
PKAN, dystonia and parkinsonism, showed age-de-
pendency, as previously reported.1,25 Patients with 
parkinsonism tended to have a later age of onset 
than patients in the dystonia-predominant group, 
while adolescent patients or patients in early adult-
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hood demonstrated more dystonia than parkinson-
ism. In addition, though the number of cases was 
limited, dystonic patients with late-adult onset tend-
ed to have less craniocervical involvement at initial 
presentation. The age of onset may influence the pre-
sentation of extrapyramidal symptoms in the atypi-
cal form of PKAN. 
Contrary to previous reports,5,6,26 neuropsychiat-
ric symptoms and cognitive impairment were un-
common and were not prominent in our series. This 
discrepancy can be explained by ethnicity-related 
differences. A previous comparative analysis noted 
a lower prevalence of these symptoms in Asians 
than in Caucasians.22 Epidemiological surveys sh-
owed lower prevalence rates of mental disorders in 
Asians.27 However, other confounding factors should 
be considered. Standardized assessment measures 
revealed that age of onset was associated with intel-
lectual and adaptive functioning.28 A younger age at 
onset of the disease was associated with a greater 
degree of cognitive impairment.1 Neuropsychiatric 
symptoms can be early presenting signs of adoles-
cence.1 Patients enrolled in this study were much 
older than those of previous reports.5,6,22,26 Most of 
them revealed stable preserved cognition and be-
havior except for two siblings with an age of onset in 
the mid-teenage years. Patients who survive into 
middle or old age should not be assumed to have a 
progressive dementia.29 However, they may be un-
derdiagnosed due to insufficient evaluation. Fur-
ther systematic assessment is warranted to determine 
the ethnic differences in cognitive and psychiatric 
symptoms.
The p.R440P and p.D378G mutations are two ma-
jor mutations representing approximately 50% of 
the mutated alleles. Most of the mutations were dif-
ferent from those reported in Caucasians.6,22,26 The 
common mutations (p.G521R and p.T528M) found 
in Caucasians have not been found in any Korean 
PKAN patients so far. The p.D378G mutation is also 
a frequent mutation in Chinese individuals and 
most likely represents a hotspot in PKAN patients 
from Eastern Asia.22,30 The p.R440P mutation may 
be a founder genotype in the Korean population.15 
This mutation was associated with both classic and 
atypical phenotypes.15 Notably, most patients carry-
ing the p.D378G mutation had a late-onset, atypical 
form of PKAN.30 Previous studies have shown that 
the locations of the missense mutations correlated 
with the residual activity of pantothenate kinase and 
the age of onset.26,31 The enzymatic activity of the 
p.D378G mutation should be determined to con-
firm the association of this mutation with the atypi-
cal clinical phenotype. It has been shown that two 
null mutations result in a loss of enzyme activity and 
lead to early-onset classic disease.6,26 However, no 
Korean pediatric patients with classic PKAN had 
two predicted loss-of-function alleles. Other genetic 
modifiers and environmental factors may also be 
involved.
Dystonia and parkinsonism showed limited re-
sponses to medications. The preservation of nigros-
triatal dopaminergic integrity can be associated with 
limited benefits of dopaminergic drugs. Isolated 
FOG with drug responsiveness is the most striking 
presenting feature in our series, although the exact 
mechanism remains uncertain.7,17 GPi-DBS perform-
ed in three patients was shown to be partially effec-
tive for relieving dystonic symptoms. The patients 
exhibited a sustained positive response to GPi-DBS 
for a 3- to 5-year follow-up period. Previous studies 
have demonstrated the efficacy of bilateral GPi-DBD 
for the treatment of dystonia in patients with PKAN, 
although the effect was not as great as the benefit 
reported in patients with primary generalized dys-
tonia.15,32 However, most reports are limited by short 
periods of observation. Additional follow-up data 
in this study add to the evidence supporting the 
long-term benefit.33 
In this study, we attempted a more detailed anal-
ysis of clinical manifestations in Korean adults with 
atypical PKAN, and we found considerable pheno-
typic heterogeneity. Some characteristic symptoms 
of the atypical form tended to show an age-depen-
dent presentation. However, the present study is 
limited because every detail of the clinical severities 
could not be obtained as our data were gathered ret-
rospectively from medical records and from a re-
view of literatures. Clinical rating scales primarily fo-
cused on PKAN or well-structured registries should 
be used for the clearer delineation of the severity 
and natural history of this disease.1 
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